Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application covering methods of selecting and treating patients with ovarian, primary liver, kidney and thyroid cancers using its investigational therapy LP-184 (zirdafulven) based on a three-gene biomarker signature. The allowed claims cover the use of elevated expression of PTGR1, PTPN14 and ASPH to identify patients who may benefit from treatment with LP-184.
Lantern said its RADR artificial intelligence platform helped identify the biomarker signature used in the patent, supporting the development of a precision medicine approach for LP-184. The company reported a 45% disease control rate among patients treated at or above the effective therapeutic dose in its Phase 1a trial and plans to advance LP-184 into multiple Phase 1b/2 precision oncology studies during 2026 while continuing to expand its intellectual property portfolio.
This patent allowance underscores Lantern Pharma's commitment to leveraging AI and machine learning to transform cancer therapy development. The RADR platform, which integrates multi-omics data and clinical insights, enables the identification of biomarkers that predict patient response, potentially increasing clinical trial success rates and reducing development costs. By securing intellectual property around these biomarker-driven methods, Lantern strengthens its competitive position in precision oncology.
The implications of this announcement are significant for patients with hard-to-treat cancers. The three-gene signature provides a molecular tool to match LP-184 to patients most likely to respond, moving beyond traditional one-size-fits-all approaches. For investors, the patent allowance adds value to Lantern's pipeline and validates its AI-driven drug development strategy, potentially attracting partnership opportunities. The company's plan to initiate Phase 1b/2 trials in 2026 suggests a clear path forward for clinical validation.
Lantern Pharma Inc. (NASDAQ: LTRN) is a clinical-stage precision oncology company leveraging AI, machine learning, and its proprietary RADR platform. The company's clinical pipeline includes LP-184, LP-284, and LP-300. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern's wholly owned CNS-focused subsidiary. Additionally, Lantern's withZeta.ai platform is commercially available as a subscription-based research platform, representing a new revenue stream.
The full press release can be viewed at https://ibn.fm/LRGUo. For more information about Lantern Pharma, visit their newsroom at https://ibn.fm/LTRN.
